Crinetics Pharmaceuticals Grants $577,000 Severance and Bonus Eligibility to Departing Chief Medical Officer

Reuters

Yesterday

Crinetics Pharmaceuticals Grants $577,000 Severance and Bonus Eligibility to Departing Chief Medical Officer

Crinetics Pharmaceuticals Inc. has announced new compensation terms for Dana Pizzuti, M.D., as she steps down from her role as Chief Medical and Development Officer effective December 31, 2025. Under a Transition Agreement, Dr. Pizzuti will receive $577,000 in cash severance, equivalent to twelve months of her current base salary. She will also be eligible for an annual cash bonus for 2025, a prorated bonus for 2026, reimbursement of up to $15,000 for legal fees related to the agreement, COBRA premium reimbursements for up to twelve months, and payment of up to $6,500 for a Board of Directors development training course. Dr. Pizzuti will continue with the company as a Strategic Regulatory and Development Advisor starting January 1, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Crinetics Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001658247-25-000022), on December 17, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2592468639"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2592468639\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2592468639?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-18 06:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2592468639","market":"nz","top_or_hot":-1,"title":"Crinetics Pharmaceuticals Grants $577,000 Severance and Bonus Eligibility to Departing Chief Medical Officer","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Crinetics Pharmaceuticals Grants $577,000 Severance and Bonus Eligibility to Departing Chief Medical Officer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/CRNX\">Crinetics Pharmaceuticals Inc.</a> has announced new compensation terms for Dana Pizzuti, M.D., as she steps down from her role as Chief Medical and Development Officer effective December 31, 2025. Under a Transition Agreement, Dr. Pizzuti will receive $577,000 in cash severance, equivalent to twelve months of her current base salary. She will also be eligible for an annual cash bonus for 2025, a prorated bonus for 2026, reimbursement of up to $15,000 for legal fees related to the agreement, COBRA premium reimbursements for up to twelve months, and payment of up to $6,500 for a Board of Directors development training course. Dr. Pizzuti will continue with the company as a Strategic Regulatory and Development Advisor starting January 1, 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Crinetics Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001658247-25-000022), on December 17, 2025, and is solely responsible for the information contained therein.</span></i>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Crinetics Pharmaceuticals Grants $577,000 Severance and Bonus Eligibility to Departing Chief Medical Officer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCrinetics Pharmaceuticals Grants $577,000 Severance and Bonus Eligibility to Departing Chief Medical Officer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-18 06:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Crinetics Pharmaceuticals Grants $577,000 Severance and Bonus Eligibility to Departing Chief Medical Officer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/CRNX\">Crinetics Pharmaceuticals Inc.</a> has announced new compensation terms for Dana Pizzuti, M.D., as she steps down from her role as Chief Medical and Development Officer effective December 31, 2025. Under a Transition Agreement, Dr. Pizzuti will receive $577,000 in cash severance, equivalent to twelve months of her current base salary. She will also be eligible for an annual cash bonus for 2025, a prorated bonus for 2026, reimbursement of up to $15,000 for legal fees related to the agreement, COBRA premium reimbursements for up to twelve months, and payment of up to $6,500 for a Board of Directors development training course. Dr. Pizzuti will continue with the company as a Strategic Regulatory and Development Advisor starting January 1, 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Crinetics Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001658247-25-000022), on December 17, 2025, and is solely responsible for the information contained therein.</span></i>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nNDL1Cxtvd:1","article_id":"2592468639","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2592468639","pubTimestamp":1766008846,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Crinetics Pharmaceuticals Inc. has announced new compensation terms for Dana Pizzuti, M.D., as she steps down from her role as Chief Medical and Development Officer effective December 31, 2025. Under a Transition Agreement, Dr. Pizzuti will receive $577,000 in cash severance, equivalent to twelve months of her current base salary. She will also be eligible for an annual cash bonus for 2025, a prorated bonus for 2026, reimbursement of up to $15,000 for legal fees related to the agreement, COBRA premium reimbursements for up to twelve months, and payment of up to $6,500 for a Board of Directors development training course. Dr. Pizzuti will continue with the company as a Strategic Regulatory and Development Advisor starting January 1, 2026.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","CRNX":"Crinetics Pharmaceuticals Inc.","BK4007":"制药"},"translate_title":"Crinetics Pharmaceuticals向即将离任的首席医疗官授予577,000美元的遣散费和奖金资格","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRNX":0.9},"content_text":"Crinetics Pharmaceuticals Grants $577,000 Severance and Bonus Eligibility to Departing Chief Medical Officer\n    \n\nCrinetics Pharmaceuticals Inc. has announced new compensation terms for Dana Pizzuti, M.D., as she steps down from her role as Chief Medical and Development Officer effective December 31, 2025. Under a Transition Agreement, Dr. Pizzuti will receive $577,000 in cash severance, equivalent to twelve months of her current base salary. She will also be eligible for an annual cash bonus for 2025, a prorated bonus for 2026, reimbursement of up to $15,000 for legal fees related to the agreement, COBRA premium reimbursements for up to twelve months, and payment of up to $6,500 for a Board of Directors development training course. Dr. Pizzuti will continue with the company as a Strategic Regulatory and Development Advisor starting January 1, 2026.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Crinetics Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001658247-25-000022), on December 17, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}